Objectives: We aimed to evaluate the effectiveness, safety and tolerability of guselkumab in a real-life setting.Methods: A prospective, observational, single-center, real-life study including patients under guselkumab treatment from October 2018 to January 2020 was conducted.Results: Twenty-three patients with moderate-to-severe psoriasis were enrolled and twenty-two continued the treatment until week 44. One patient discontinued for increase in liver enzymes. At baseline, mean PASI score was 15.1 ± 6.1, which reduced up to 3.2 ± 1.9 at week 12 (p < 0.001) and 0.8 ± 0.7 at week 44 (p < 0.001). BSA reduced from 36.4 ± 13.6 at baseline, to 8.3 ± 7.4 at week 12 (p < 0.001), up to 2.2 ± 1.4 at week 44 (p < 0.001). A total of 4 patients (17.4%) experienced mild blood tests alterations and 6 subjects (26%) experienced potential adverse events (AEs). No AEs required guselkumab discontinuation. No cases of serious AEs, injection site reaction, candida, malignancy, cardiovascular events were reported.Conclusions: Patients under guselkumab therapy reach an optimal clinical response, even in a real-life and long-term setting.

Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience

Megna, Matteo;Fabbrocini, Gabriella;Cinelli, Eleonora;Camela, Elisa;Ruggiero, Angelo
2020

Abstract

Objectives: We aimed to evaluate the effectiveness, safety and tolerability of guselkumab in a real-life setting.Methods: A prospective, observational, single-center, real-life study including patients under guselkumab treatment from October 2018 to January 2020 was conducted.Results: Twenty-three patients with moderate-to-severe psoriasis were enrolled and twenty-two continued the treatment until week 44. One patient discontinued for increase in liver enzymes. At baseline, mean PASI score was 15.1 ± 6.1, which reduced up to 3.2 ± 1.9 at week 12 (p < 0.001) and 0.8 ± 0.7 at week 44 (p < 0.001). BSA reduced from 36.4 ± 13.6 at baseline, to 8.3 ± 7.4 at week 12 (p < 0.001), up to 2.2 ± 1.4 at week 44 (p < 0.001). A total of 4 patients (17.4%) experienced mild blood tests alterations and 6 subjects (26%) experienced potential adverse events (AEs). No AEs required guselkumab discontinuation. No cases of serious AEs, injection site reaction, candida, malignancy, cardiovascular events were reported.Conclusions: Patients under guselkumab therapy reach an optimal clinical response, even in a real-life and long-term setting.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/814404
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 29
social impact